Woodman C L, Noyes R
Department of Psychiatry, University of Iowa, Iowa City 52242.
J Clin Psychiatry. 1994 Apr;55(4):134-6.
To determine the efficacy of divalproex sodium in the treatment of panic disorder, divalproex sodium was administered in a 6-week open clinical trial to 12 patients who had a primary DSM-III-R diagnosis of panic disorder.
Treatment was begun at 500 mg of divalproex sodium daily and was increased according to clinical response and side effects. Clinicians completed a Clinical Global Impressions Scale weekly and a Hamilton Rating Scale for Anxiety every other week. Patients completed a panic-attack diary and a Brief Symptom Inventory weekly.
All 12 patients completed the study, and all were moderately to markedly improved. Measures of panic attacks and anxiety improved more quickly and robustly than measures of phobic avoidance. Eleven of the 12 patients elected to remain in treatment and at 6-month follow-up had sustained improvement.
These findings suggest that valproic acid may be effective for the treatment of panic disorder. Double-blind studies will be required to further verify these findings.
为确定丙戊酸二钠治疗惊恐障碍的疗效,在一项为期6周的开放性临床试验中,对12例原发性DSM-III-R诊断为惊恐障碍的患者给予丙戊酸二钠治疗。
治疗从每日500毫克丙戊酸二钠开始,根据临床反应和副作用进行增加。临床医生每周完成一次临床总体印象量表,每隔一周完成一次汉密尔顿焦虑量表。患者每周完成一次惊恐发作日记和简明症状量表。
所有12例患者均完成研究,且均有中度至显著改善。惊恐发作和焦虑的测量指标比恐惧回避的测量指标改善得更快、更明显。12例患者中有11例选择继续治疗,在6个月的随访中病情持续改善。
这些发现表明丙戊酸可能对惊恐障碍有效。需要进行双盲研究以进一步验证这些发现。